Nitrogen Scavengers: History, Clinical Considerations and Future Prospects
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.70110 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Sven Klassa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Urea Cycle Disorders, Inborn, Hyperammonemia, Nitrogen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, ITINERARE, University Research Priority Program of the University of Zurich, Citrin Foundation.
Abstract (Originalsprache)
Nitrogen scavengers play a critical role in treating acute and chronic hyperammonemia, especially in urea cycle disorders (UCDs), where impaired ammonia detoxification leads to toxic nitrogen accumulation. These agents complement low‐protein diets and urea cycle intermediates. Sodium benzoate and sodium phenylacetate are the main scavengers, conjugating with glycine and glutamine to form hippurate and phenylacetylglutamine, which are excreted in urine. This therapeutic approach, introduced in the 1980s, was based on early findings linking benzoate to reduced urea excretion. Nitrogen scavengers are also used in secondary hyperammonemia from organic acidemias and fatty acid oxidation disorders, though they may become increasingly ineffective in progressing liver failure due to their reliance on hepatocyte function. To improve tolerability, phenylbutyrate was developed as an oral alternative to phenylacetate and is available in sodium‐bound and prodrug forms, but issues with taste and side effects persist. While effective, current treatments target nitrogenous waste products rather than ammonia directly, offering an avenue of future drug development for UCDs. This review discusses the chemical properties, clinical use, and limitations of nitrogen scavengers, hereby focusing on phenylacetate and related substances, and highlights the need for improved therapies, including approaches that directly target ammonia removal. For the benefit of readers already experienced in nitrogen scavengers for UCDs, we also include considerations concerning the use of these drugs in animal experiments and a viewpoint on ornithine phenylacetate as a related substance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Sven Klassa, Johannes Häberle
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- ITINERARE, University Research Priority Program of the University of Zurich
- Citrin Foundation
Zitieren
APA
Klassa, S., & Häberle, J. (2025). Nitrogen Scavengers: History, Clinical Considerations and Future Prospects. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70110
Vancouver
Klassa S, Häberle J. Nitrogen Scavengers: History, Clinical Considerations and Future Prospects. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70110
BibTeX
@article{Klassa2025,
author = {Klassa, Sven and Häberle, Johannes},
title = {Nitrogen Scavengers: History, Clinical Considerations and Future Prospects},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.70110}
}
EUVIMED